More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Primary Antibody Diluent
Primary Antibody Diluent

Primary Antibody Diluent

GTX28208
GeneTex
Product group Chemicals
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    GeneTex
  • Product Name
    Primary Antibody Diluent
  • Delivery Days Customer
    9
  • Application Supplier Note
    Preparation of Reagent: Bring the diluent to room temperature and mix thoroughly before use. No further preparation is required. Procedure: 1) Pour the diluent in a clean glass container. 2) Add concentrated primary antibody directly in the diluent and mix thoroughly. 3) Diluted antibody is ready to use now and should be stored at 2-81/4 C for further use.
  • Applications
    ImmunoHistoChemistry
  • Certification
    Research Use Only
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352200

References

  • Kukida M, Amioka N, Ye D, et al. Manipulation of components of the renin angiotensin system in renal proximal tubules fails to alter atherosclerosis in hypercholesterolemic mice. Front Cardiovasc Med. 2023,10:1250234. doi: 10.3389/fcvm.2023.1250234
    Read this paper
  • Besse HC, Barten-van Rijbroek AD, van der Wurff-Jacobs KMG, et al. Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo. Cancers (Basel). 2019,11(10). doi: 10.3390/cancers11101512
    Read this paper
  • Zhang L, Wang XI, Ding J, et al. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Ann Diagn Pathol. 2019,40:143-151. doi: 10.1016/j.anndiagpath.2019.04.004
    Read this paper
  • Liu X, Wang X, Ding J, et al. FOXP3 and CD25 double staining antibody cocktails identify regulatory T cells in different types of tumor tissues using tissue microarrays. Ann Diagn Pathol. 2019,38:67-70. doi: 10.1016/j.anndiagpath.2018.11.005
    Read this paper
  • Hoogsteen IJ, Marres HA, van den Hoogen FJ, et al. Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance. Int J Radiat Oncol Biol Phys. 2012,84(3):807-14. doi: 10.1016/j.ijrobp.2012.01.002
    Read this paper
  • Nijkamp MM, Hoogsteen IJ, Span PN, et al. Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. Radiother Oncol. 2011,101(1):165-70. doi: 10.1016/j.radonc.2011.06.022
    Read this paper
  • Hoeben BA, Kaanders JH, Franssen GM, et al. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J Nucl Med. 2010,51(7):1076-83. doi: 10.2967/jnumed.109.073189
    Read this paper
  • Troost EG, Bussink J, Slootweg PJ, et al. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. J Nucl Med. 2010,51(5):713-9. doi: 10.2967/jnumed.109.071910
    Read this paper

Datasheet

Download Datasheet

FAQ

Go to our frequently asked questions